Prochlorperazine

證據等級: L5

預測適應症: 10 個

Prochlorperazine: From Antiemetic/Antipsychotic Use (Data Gap) to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Prochlorperazine is a phenothiazine dopamine D2 antagonist; its formal original indication could not be confirmed in this evidence pack, but its known pharmacological class is used for nausea/vomiting and psychosis/sedation. The TxGNN model assigns a very high score (99.998%) to Retinal Dystrophy with or without Extraocular Anomalies, but the model’s own rationale flags this association as likely spurious co-occurrence noise — no clinical trials, and none of the associated literature actually discusses prochlorperazine. Evidence level is L5 (model prediction only) and the recommended decision is Hold.

Quick Overview

Item	Content
Original Indication	Not available — no market license data; drug’s pharmacological class is historically used as antiemetic/antipsychotic (dopamine D2 antagonist)
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	99.998% (rank 138 of all candidates)
Evidence Level	L5
Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for prochlorperazine is not available as a structured field (flagged as a High-severity data gap). Based on information embedded in the model’s own reasoning output, prochlorperazine is a phenothiazine-class dopamine D2 receptor antagonist, traditionally used for antiemetic and sedative/antipsychotic purposes.

The top-ranked predicted indication — retinal dystrophy with or without extraocular anomalies — is a largely congenital, genetically-driven retinal/ocular structural disorder. There is no known pharmacological pathway by which a D2-antagonist antiemetic would influence retinal developmental biology or congenital extraocular structural anomalies. The evidence pack’s own repurposing rationale explicitly states this is likely a spurious knowledge-graph co-occurrence rather than a genuine drug–disease relationship: the 14 associated publications are general ophthalmology reviews/case reports (orbital infections, diplopia, congenital ptosis, CFEOM, etc.) and none of them mention prochlorperazine.

Of note, a lower-ranked candidate in this evidence pack — manic bipolar affective disorder (rank 10, score 99.98%, evidence level L4) — has meaningfully stronger mechanistic plausibility: phenothiazines as a class were historically used for acute mania before modern antipsychotics existed, and one directly relevant case report (PMID 13617778) describes a confusional dream-like reaction specifically attributed to prochlorperazine in a patient with mild manic-depressive illness. This suggests the model’s overall signal quality is mixed — some predictions reflect real pharmacology, while the top-ranked candidate here does not.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The following literature is linked to retinal dystrophy with or without extraocular anomalies in the evidence pack. None of these publications discuss prochlorperazine directly; they are general ophthalmology/genetics reviews and case reports retrieved via disease-term co-occurrence.

PMID	Year	Type	Journal	Key Findings
33806565	2021	Case Series	Int J Mol Sci	Optic nerve/retinal abnormalities in congenital fibrosis of extraocular muscles (CFEOM); no drug relevance
38321238	2024	Review	Pediatric Radiology	Imaging review of pediatric congenital ocular pathologies
38249493	2023	Review	Taiwan J Ophthalmol	Congenital anomalies of lens shape
36892533	2023	pending	Invest Ophthalmol Vis Sci	MAB21L1 mutations causing autosomal dominant ocular BAMD syndrome (genetic, not pharmacologic)
36116851	2022	pending	Semin Ultrasound CT MR	Anatomy/pathology review of the oculomotor nerve
30196776	2018	Review	J Binocul Vis Ocul Motil	Congenital cranial dysinnervation disorders
24932988	2014	Review	Am J Ophthalmol	Maculopathy associated with cavitary optic disc anomalies
24413161	2014	pending	J Neuroophthalmol	Congenital trochlear-oculomotor synkinesis
22241537	2012	Review	Klin Monbl Augenheilkd	Congenital ptosis review
20127583	2010	Review	Semin Neurol	Diplopia diagnostic approach

Market Information

The drug is currently not marketed under this evidence pack’s regulatory jurisdiction — total_licenses = 0, no license records available. No dosage form or approved-indication data could be extracted.

Safety Considerations

Formal safety data (key warnings, contraindications, drug interaction database) could not be retrieved for this evidence pack — flagged as a Blocking-severity data gap (DG001): TFDA/local label warnings and contraindications require manual PDF retrieval and have not yet been completed. DDI query returned no results (query_status: not_found).

Please refer to the official package insert for safety information once available.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (retinal dystrophy with extraocular anomalies) has no clinical trials, no directly relevant literature, and the model’s own rationale identifies it as likely spurious knowledge-graph noise rather than a genuine pharmacological signal — evidence level L5, decision stage S0. This candidate should not advance without independent mechanistic or preclinical justification.

To proceed, the following is needed:

Resolve blocking data gap DG001: retrieve official label warnings/contraindications before any safety-relevant decision (S1) can be made
Resolve data gap DG002: confirm mechanism of action and original approved indication(s) from DrugBank/regulatory source
If pursuing further, consider re-scoping toward the manic bipolar affective disorder candidate (rank 10, L4, S1 “Research Question”), which has class-level mechanistic plausibility and at least one drug-specific case report, rather than the top-ranked but mechanistically unsupported ophthalmologic candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.